AZN241108P71000
- 4.70
- +3.78+410.87%
AstraZeneca Newsroom
Astrazeneca releases trial data on oral weight loss medication, with patients using the drug for four weeks experiencing nearly a 6% weight reduction.
①Astrazeneca reported that its oral small molecule weight loss drug AZD5004/ECC5004 reduced the average weight of patients by 5.8% within four weeks in early studies, and showed good tolerability; ② Astrazeneca acquired the global exclusive rights to the drug from Creentech for 2 billion US dollars last year, which is currently in the clinical research stage.
How to Boost Your Portfolio With Top Medical Stocks Set to Beat Earnings
AstraZeneca (AZN) Gets a Sell From Deutsche Bank
AstraZeneca Says Obesity Pill Well Tolerated by Type-2 Diabetes Patients, Competitive
AstraZeneca's Promising Obesity Treatment Advances Justify Buy Rating: Analyst Report
Express News | Huaren pharmaceutical: Sodium Aescinate injection obtained Pharmaceutical registration certificate.
Futu Morning Post | Countdown to the election! The panic index VIX is burning high and uncertainty is haunting the market nerves; Up nearly 13% after hours! Palantir raises full-year revenue guidance
Jpmorgan warns: If Trump wins on Wednesday, the Fed may pause the easing cycle as early as December; Will the US stock market hit new highs after the election? Jpmorgan: FOMO psychology boosts, S&P may hit 6100 points by the end of the year; US polls: Harris and Trump are neck and neck in key 'swing states'.
US stocks closed: Trump, Harris concept stocks rose together, Chinese concept stocks remained stable and rose.
1. The market is filled with a wait-and-see attitude, with all three major indexes collectively falling. 2. Trump's media technology group rebounded after hitting bottom. 3. Photovoltaic and clean energy concept stocks strengthened collectively. 4. Reports claim that Nvidia will distribute Super Micro Computer orders to other suppliers.
UBS Reaffirms Their Sell Rating on AstraZeneca (AZN)
Sector Update: Health Care Stocks Softer in Afternoon Trading
AstraZeneca Unveils Early Data From Chinese-Firm Partnered Oral Weight Loss Drug
AstraZeneca Meet The Management: Weight Management Virtual Event Began At 10:00 Am EST
Express News | Astrazeneca: Research results indicate that the subjects showed very good tolerance to oral weight loss medication.
AstraZeneca Says Experimental Obesity Pill Safe And Tolerable In Early-Stage Trial; Shares Spike Higher
AstraZeneca Says Obesity Pill Well-Tolerated, Highly Competitive
Express News | The head of AstraZeneca Pharmaceuticals Co., Ltd. has been changed last month, with Meng Yihua replacing Wang Lei.
Are Options Traders Betting on a Big Move in AstraZeneca (AZN) Stock?
Stock market anomaly | viking therapeutics (VKTX.US) surged 24% pre-market, significant early research effectiveness of oral weight loss drugs.
Biotechnology company Viking Therapeutics' stock price rose 23.90% in pre-market trading as of Monday.
Viking (VKTX.US) weight loss drug research results are significant, challenging novo-nordisk a/s (NVO.US) and eli lilly and co (LLY.US) market positions.
viking therapeutics announced that its investigational drug VK2735 can effectively reduce patient weight more at higher doses compared to the early formulation.
Astrazeneca (AZN) Rises But Trails Market: What Investors Should Know